|Bid||0.9235 x 200|
|Ask||0.9300 x 800|
|Day's Range||0.9100 - 0.9488|
|52 Week Range||0.8800 - 2.0800|
|PE Ratio (TTM)||-0.71|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
At the beginning of 2015, Durham’s Heat Biologics (HTBX) announced a collaboration with San Diego-based biotechnology company OncoSec Medical Incorporated (ONCS). The companies announced this week that the collaboration – which is aimed at evaluating the delivery of immunotherapy vaccines being developed by Heat using OncoSec’s ImmunoPulse platform – is showing promise based on new preclinical data.
An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.